Physician profile
Amanda E Hanor
NPI 1831605773
$8,947.25
in general payments reported to CMS, 2019-2025
25 companies · $1,699 in 2025
The $1,699 reported for 2025 was more than what 89% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,306 · 2022: $1,500 · 2023: $2,168 · 2024: $2,275 · 2025: $1,699.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,473 · Education: $668.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,473.42 |
| Education | $668.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,906.11 | 2021-2025 | |
| Janssen Biotech, INC. | $1,683.68 | 2021-2025 | Tremfya |
| E.R. Squibb & Sons, L.L.C. | $989.75 | 2022-2025 | Sotyktu |
| Pfizer INC. | $804.40 | 2021-2025 | |
| Sun Pharmaceutical Industries INC. | $561.88 | 2021-2025 | Winlevi, Absorica Ld |
| Leo Pharma INC. | $443.34 | 2021-2025 | Adbry, Anzupgo |
| Novartis Pharmaceuticals Corporation | $376.59 | 2021-2025 | |
| Galderma Laboratories, L.P. | $373.93 | 2021-2025 | Nemluvio, Aklief |
| Amgen INC. | $348.06 | 2022-2024 | Otezla, Enbrel |
| Genzyme Corporation | $261.63 | 2021-2025 | |
| Dermavant Sciences, INC. | $255.80 | 2023-2024 | Vtama |
| Lilly USA, LLC | $243.89 | 2023-2025 | Taltz, Olumiant, Ebglyss |
| Ucb, INC. | $173.68 | 2021-2025 | Bimzelx |
| Regeneron Healthcare Solutions, INC. | $156.24 | 2021-2024 | Dupixent |
| Incyte Corporation | $83.93 | 2022-2023 | Opzelura |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arcutis Biotherapeutics, INC. | $55.33 | 2023-2024 | Zoryve |
| Sandoz INC. | $43.85 | 2023 | Hyrimoz |
| Kyowa Kirin, INC. | $40.60 | 2021-2023 | Poteligeo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.90 | 2025 | Spevigo |
| Dermira, INC. | $24.80 | 2021 | |
| Epi Health, LLC | $22.72 | 2021 | |
| Mayne Pharma Commercial LLC | $22.58 | 2021 | |
| Genentech, INC. | $18.44 | 2023 | Erivedge |
| Biocon Biologics INC | $18.21 | 2025 | Yesintek |
| Journey Medical Corporation | $11.91 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Hanor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.